Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
GammaDelta Therapeutics, a clinical-stage biotechnology company and part of Takeda, is at the forefront of discovering and developing allogeneic immunotherapies. Their innovative approach leverages the unique properties of gamma delta (γδ) T cells to target cancer and other diseases. The company focuses on advancing its pipeline of γδ T cell-based candidates to provide novel treatment options for patients with high unmet medical needs. Their research aims to harness the power of these specialized immune cells to create 'off-the-shelf' therapies.
The headquarters serves as the central hub for research and development, corporate operations, and strategic leadership for GammaDelta Therapeutics' pioneering work in γδ T cell therapies.
Located in White City Place, a prominent campus for life sciences, technology, and creative industries, offering state-of-the-art laboratory and office facilities.
The work culture at GammaDelta Therapeutics, now part of Takeda, is expected to be highly scientific, innovative, and collaborative, focusing on cutting-edge research in cell therapy. It likely combines an agile biotech spirit with the resources and structure of a large pharmaceutical company, emphasizing rigor, patient-focus, and teamwork.
The London HQ is strategically located in White City Place, a leading life sciences hub, providing access to world-class talent, research institutions, and a collaborative ecosystem. Its integration within Takeda further enhances its significance by connecting it to global R&D and clinical development capabilities.
As a Takeda company, GammaDelta Therapeutics' innovative research in gamma delta T cell therapies contributes to Takeda's global oncology pipeline. Their work supports the development of potential treatments for patients worldwide, leveraging Takeda's extensive global network for clinical development, manufacturing, and future commercialization. While its primary research and operational hub is in London, its impact and collaborations are global through the Takeda infrastructure.
WestWorks Building, White City Place, 195 Wood Lane
London
England
United Kingdom
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, GammaDelta Therapeutics' leadership includes:
GammaDelta Therapeutics has been backed by several prominent investors over the years, including:
Following its acquisition and integration into Takeda in late 2022, GammaDelta Therapeutics' leadership structure has evolved. Key leadership roles for the gamma delta T cell programs are now embedded within Takeda's broader R&D and oncology organization. No major distinct GammaDelta Therapeutics C-level executive hires or exits have been publicly announced in the last 12 months (May 2023 - May 2024).
Discover the tools GammaDelta Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Common email formats for GammaDelta Therapeutics likely follow standard professional patterns. Given its domain gammadeltatx.com, a probable format would be combining first name and last name.
firstname.lastname@gammadeltatx.com
Format
jane.doe@gammadeltatx.com
Example
75%
Success rate
Takeda Pharmaceuticals • November 9, 2023
Takeda presented positive initial data from the Phase 1 clinical trial of GDX012, an allogeneic, variable delta 1 (Vδ1) gamma-delta (γδ) T-cell therapy, in patients with relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). GDX012 originated from GammaDelta Therapeutics' platform....more
Fierce Biotech • November 9, 2023
Fierce Biotech reported on Takeda's presentation of Phase 1 data for GDX012, a gamma-delta T-cell therapy acquired through the GammaDelta Therapeutics buyout. The therapy showed early signs of clinical activity and a manageable safety profile in treating acute myeloid leukemia and myelodysplastic syndromes....more
Takeda Pharmaceuticals • October 4, 2022
Takeda announced the successful completion of its acquisition of GammaDelta Therapeutics Ltd., a company focused on exploiting the unique properties of gamma delta (γδ) T cells for immunotherapy. This acquisition aimed to further accelerate the development of Takeda’s novel immuno-oncology portfolio....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including GammaDelta Therapeutics, are just a search away.